Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study

Nicola Cascavilla,1 Valerio De Stefano,2 Fabrizio Pane,3 Alessandro Pancrazzi,4 Alessandra Iurlo,5 Marco Gobbi,6 Francesca Palandri,7 Giorgina Specchia,8 A Marina Liberati,9 Mariella D’Adda,10 Gianluca Gaidano,11 Rajmonda Fjerza,4 Heinrich Achenbach,12 Jonathan Smith,13 Paul Wilde,13 Aless...

Full description

Bibliographic Details
Main Authors: Cascavilla N, De Stefano V, Pane F, Pancrazzi A, Iurlo A, Gobbi M, Palandri F, Specchia G, Liberati AM, D’Adda M, Gaidano G, Fjerza R, Achenbach H, Smith J, Wilde P, Vannucchi AM
Format: Article
Language:English
Published: Dove Medical Press 2015-05-01
Series:Drug Design, Development and Therapy
Online Access:http://www.dovepress.com/impact-of-jak2v617f-mutation-status-on-treatment-response-to-anagrelid-peer-reviewed-article-DDDT

Internet

http://www.dovepress.com/impact-of-jak2v617f-mutation-status-on-treatment-response-to-anagrelid-peer-reviewed-article-DDDT

Similar Items